QQ客服 官方微博 反馈留言

	Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
	Zhang, Tengfei; Zhang, Lu; Xie, Yuancai; Li, Bing; Ma, Yafeng; Mao, Xinru; Wu, Da; Zhou, Qiang; Jin, Meiling; Ma, Yuxiang
刊名	DRUG DESIGN DEVELOPMENT AND THERAPY
	2019
卷号	13
关键词	EGFR alteration ALK rearrangement nonsmall cell lung cancer EML4-ALK tyrosine kinase inhibitor
ISSN号	1177-8881
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594658
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhang, Tengfei,Zhang, Lu,Xie, Yuancai,et al. Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients[J]. DRUG DESIGN DEVELOPMENT AND THERAPY,2019,13.
APA	Zhang, Tengfei.,Zhang, Lu.,Xie, Yuancai.,Li, Bing.,Ma, Yafeng.,...&Chen, Peng.(2019).Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients.DRUG DESIGN DEVELOPMENT AND THERAPY,13.
MLA	Zhang, Tengfei,et al."Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients".DRUG DESIGN DEVELOPMENT AND THERAPY 13(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。